Navigation Links
Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
Date:7/28/2008

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) announced the appointment of Paul A. Foster, M.D. as Chief Medical Officer to lead the Company's late-stage clinical development activities at Cardium's Tissue Repair Company for the MATRIX Phase 2b clinical study that is evaluating its Excellarate product candidate for the treatment of diabetic ulcers, and the AWARE Phase 3 clinical study that is evaluating its Generx product candidate as a potential treatment for recurrent myocardial ischemia. Dr. Foster, who is currently Cardium's Vice President and Medical Officer, will assume study oversight responsibilities for both Cardium's and the Tissue Repair Company's clinical programs. Dr. Robert Engler, the Company's Chief Medical Advisor who has been involved in the Generx trials since their inception, will continue to play an active role in those studies, and Dr. Randall Moreadith will continue to focus on evaluating potential new business development and medical device opportunities for the Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

"We are very pleased to have Paul head up development of our key product candidates as they move through late-stage clinical trials," stated Christopher J. Reinhard, Chief Executive Officer and Chairman of Cardium Therapeutics. "Paul's leadership and extensive clinical experience will greatly assist us as we advance our Generx candidate now in Phase 3, and Tissue Repair's Excellarate candidate, which is expected to complete its key Phase 2 study this year."

Dr. Foster was previously Chief Medical Officer and Vice President of Clinical Development and
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... FRANCISCO , May 21, 2013 ... of the American Psychiatric Association show that the ... and clinically meaningful response and remission in patients ... phase of therapy, which were maintained through one ... treatment, 62 percent of patients achieved symptomatic improvement ...
(Date:5/21/2013)... 21 de mayo de 2013 La junta ... filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, ... su junta. Guy Mayer, un ejecutivo ortopédico experimentado, será ... David Johnson , un experto refutado en ... Antes de unirse a OSI como presidente de ...
(Date:5/21/2013)... PRINCETON, N.J. , May 21, 2013 /PRNewswire/ ... consulting company, today announced that 13-year veteran ... Chief Executive Officer. Geraghty,s experience includes more than ... senior management positions with manufacturing organizations. He succeeds ... retiring after serving as Kepner-Tregoe,s Chairman of the ...
Breaking Medicine Technology:New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3
... Inc. (NYSE Amex: PTN ) announced that it ... Investment Conference / 12th Annual Healthcare Conference on Tuesday, September ... place September 12-15 at the New York Palace Hotel in ... and Chief Executive Officer of Palatin Technologies, will provide an ...
... HILL, N.C., Sept. 10 New Product Planning (NPP) ... new product development activities that set the stage for ... importance for NPP groups is medical marketing activities such ... Leading organizations understand that investing in educating the medical ...
Cached Medicine Technology:Best Practices, LLC Research Highlights Critical Role of Medical Marketing in New Product Launch Success 2
(Date:5/21/2013)... Beach, CA (PRWEB) May 21, 2013 ... 3rd Annual EB-5 Investment Summit: Dealmakers Conference in ... Dealmakers Conference will focus on exploring alternative finance ... provide the latest market, legal and economic information, ... immigration and legal professionals within the EB-5 industry. ...
(Date:5/21/2013)... Angeles, CA (PRWEB) May 21, 2013 According ... “Time to Rethink the Use of Botox,” Botox ... world since their approval in 2002 (Go to goo.gl/8iYbD). Although ... become quite popular with men. The injection makes facial wrinkles ... single Botox injection last for about three months. This means ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve ... the Creative Corridor region, is releasing results for its ... on Thursday, May 23rd at 10:30 a.m. The ... , The survey is a critical component to ... attract, nurture and retain people of diverse backgrounds, cultures ...
(Date:5/21/2013)... paper recently published in the New England Journal ... at the University of Colorado School of Medicine finds ... can be used to identify individuals at risk for ... fairly common variant of the gene for mucin-5B, a ... by the bronchial tubes. While this variant of the ...
(Date:5/21/2013)... Brazilian funding agency for scientific and technological research So ... So Paulo, announced an investment estimated in US$ 680 ... (RIDCs) for a period of up to eleven years, ... 7. , Funding for the 17 RIDCs will ... faculty, technicians, support personnel, and infrastructure). Host institutions will ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2
... SATURDAY, June 11 (HealthDay News) -- For most people, insect ... for those who are allergic to them, researchers warn. ... million people have to go to emergency departments after suffering ... American College of Allergy, Asthma and Immunology, which recently released ...
... HealthDay Reporter , FRIDAY, June 10 (HealthDay News) ... sex? That,s the finding from a new study ... of satisfaction in the bedroom. Researchers from Johns Hopkins ... than 3,200 men and women ages 18 to 26, analyzing ...
... News) -- Emotional abuse in childhood can lead to sleep ... analyzing nearly 900 adults ageD 60 and older, researchers found ... earlier were at greater risk for poor sleep quality years ... to exert an influence on our well-being decades later through ...
... 10 (HealthDay News) -- Men may be far less likely than ... they should make the effort, a Loyola University physician says. ... rates for heart disease, cancer, stroke and AIDS. But a U.S. ... to see a doctor on a regular basis. For many ...
... of medicine and director of the rheumatology division ... with colleagues from the medical center for rheumatoid ... and the blogosphere to discuss advances in the ... can be viewed at: , http://coe.musculoskeletaldisease.webdev.nyumc.org/research/whats-up-with-ra-webinar ...
... , THURSDAY, June 9 (HealthDay News) -- The U.S. Food ... a class of drugs used primarily to treat enlarged prostates, ... aggressive form of prostate cancer. In a statement released ... sold under the brand names Proscar and Propecia (sold by ...
Cached Medicine News:Health News:Insect Stings Hold Deadly Risk for Some 2Health News:Self-Confidence, Empathy May Make for Better Sex 2Health News:Self-Confidence, Empathy May Make for Better Sex 3Health News:Emotional Abuse in Childhood May Disrupt Sleep Decades Later 2Health News:Men Urged to Lead by Example and See a Doctor Regularly 2Health News:NYU Langone rheumatologists share insight with online RA community 2Health News:Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer 2Health News:Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer 3
... Eyes enzymatic cleaner is a ... removes stubborn deposits in as ... eyes enzymatic cleaner contains an ... irritating film on soft contact ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Titanium. Straight shafts with curved lower tip. Upper tip fits into positioning hole while lower jaw stabilizes the lens. Flat smooth handle with dull finish. Most popular size or model....
Medicine Products: